XNASVTYX
Market cap147mUSD
Jan 17, Last price
2.09USD
1D
10.58%
1Q
-17.72%
IPO
-88.79%
Name
Ventyx Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-193m
L+78.74%
CFO
-167m
L+68.59%
Earnings
Feb 24, 2025
Profile
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 208,935 | 113,606 | |||
Unusual Expense (Income) | |||||
NOPBT | (208,935) | (113,606) | |||
NOPBT Margin | |||||
Operating Taxes | (470) | ||||
Tax Rate | |||||
NOPAT | (208,935) | (113,136) | |||
Net income | (192,962) 78.74% | (107,956) 37.76% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 48,408 | 168,039 | |||
BB yield | -33.48% | -9.77% | |||
| Debt | |||||
Debt current | 1,001 | 412 | |||
Long-term debt | 24,011 | 2,704 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (227,208) | (392,169) | |||
| Cash flow | |||||
Cash from operating activities | (166,522) | (98,771) | |||
CAPEX | (514) | (275) | |||
Cash from investing activities | 100,940 | (74,931) | |||
Cash from financing activities | 53,329 | 167,772 | |||
FCF | (219,262) | (114,826) | |||
| Balance | |||||
Cash | 252,220 | 356,613 | |||
Long term investments | 38,672 | ||||
Excess cash | 252,220 | 395,285 | |||
Stockholders' equity | (419,231) | (227,342) | |||
Invested Capital | 675,660 | 2,675 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 58,543 | 52,471 | |||
Price | 2.47 -92.47% | 32.79 65.11% | |||
Market cap | 144,601 -91.60% | 1,720,524 71.86% | |||
EV | (82,607) | 1,328,355 | |||
EBITDA | (207,994) | (113,136) | |||
EV/EBITDA | 0.40 | ||||
Interest | 4,710 | ||||
Interest/NOPBT | |||||